Phaseline

Targets › DRD2

DRD2 (Dopamine receptor D2): drug programs, companies and trials

64 programs from 52 companies in 119 trials: 41 Phase 3, 35 Phase 2, 32 Phase 4, 11 Phase 1; Psychiatry, Neurology, Other; next expected readout Nov 2026.

G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P14416)

Open in Phaseline: the race on DRD2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vanda Pharmaceuticalsiloperidone
Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR2APhase 4Schizophrenia; HypertensionNov 2026
Sanliurfa Education and Research Hospitalmetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 4Intraoperative Nausea-retching-vomiting EpisodesJan 2027
The University of Texas Health Science Center at San AntonioQuetiapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Parkinson's Disease PsychosisFeb 2027
New York State Psychiatric InstituteOlanzapine-samidorphan
Atypical antipsychotic (D2 dopamine receptor antagonist) combined with opioid antagonist (
DRD2, OPRK1Phase 4Schizophenia DisorderApr 2027
University of Texas Southwestern Medical Centerclozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4SchizophreniaApr 2027
The Chaim Sheba Medical Centerrisperidone
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Velocardiofacial SyndromeAug 2027
Centre Hospitalier Universitaire, Amiensclozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4ClozapineSep 2027
Centre for Addiction and Mental HealthClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4SchizophreniaSep 2027
Centre for Addiction and Mental HealthPaliperidone
Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR2APhase 4Schizophrenia and Related DisordersSep 2027
Centre for Addiction and Mental HealthRisperidone
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Schizophrenia and Related DisordersSep 2027
Dennis M. McNamara, MD, MSBromocriptine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 4Peripartum Cardiomyopathy, PostpartumJun 2028
New York State Psychiatric InstituteClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4SchizophreniaJun 2028
Dr. Inge WinterClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4Schizophrenia and Related DisordersJun 2028
Northwell Healtharipiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 4Psychosis; Acute; Schizophenia DisorderDec 2029
Northwell Healthrisperidone
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Psychosis; Acute; Schizophenia DisorderDec 2029
Jimmi NielsenClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4SchizophreniaDec 2029
Massachusetts General HospitalAripiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 4Bipolar I DisorderFeb 2030
Massachusetts General HospitalLurasidone
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4Bipolar I DisorderFeb 2030
Massachusetts General HospitalQuetiapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Bipolar I DisorderFeb 2030
Northwell Healthclozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4Schizophenia DisorderJul 2030
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityFlupentixol-Melitracen
Antipsychotic-antidepressant combination; flupentixol is a dopamine antagonist, melitracen
DRD2, SLC6A3Phase 4Thyroid-Associated Ophthalmopathy–
Massachusetts General HospitalPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 4Adrenoleukodystrophy–
Changchun GeneScience PharmaceuticalCabergoline
Dopamine D2 receptor agonist
DRD2Phase 3Hyperprolactinemia; Prolactinoma; Pituitary Neoplasms; Gynecologic Disease …Nov 2026
Jimma UniversityBromocriptine mesylate
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Dilated CardiomyopathyNov 2026
Gedeon RichterCariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 3Schizophrenia; Depression, Bipolar; Bipolar I DisorderDec 2026
AbbVieCariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 3DepressionMar 2027
Intra-Cellular TherapiesLumateperone
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor
HTR2A, DRD2, SLC6A4Phase 3Major Depressive Disorder; Irritability Associated With Autism Spectrum Disorder; Bipolar Depression; Schizophrenia …Apr 2027
LB PharmaceuticalsLB-102
Atypical antipsychotic; dopamine D2/D3 receptor antagonist
DRD2, DRD3Phase 3Schizophrenia; Bipolar I DisorderJun 2027
Shanghai Mental Health CenterAripiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 3Treatment-resistant Schizophrenia; Obsessive-Compulsive DisorderJun 2027
OtsukaBrexpiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 3Acute SchizophreniaSep 2027
M.D. Anderson Cancer CenterDomperidone
Dopamine D2 receptor antagonist
DRD2Phase 3Digestive System DisorderOct 2027
Affiliated Hospital of Qinghai UniversityMetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 3NauseaDec 2027
PrileniaPridopidine
Dopamine D2 receptor modulator
DRD2Phase 3Amyotrophic Lateral Sclerosis; Huntington DiseaseMar 2028
Foundation for Advancing Veterans' Health ResearchQuetiapine Fumarate
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 3Mild Traumatic Brain InjuryJun 2028
Gustave Roussy, Cancer Campus, Grand ParisONC201
DRD2 antagonist; also exhibits TRAIL pathway activation
DRD2Phase 3Diffuse Intrinsic Pontine GliomaSep 2028
Daniel LindqvistPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Bipolar Disorder (BD)Dec 2029
Shanghai Mental Health CenterAmisulpride
Atypical antipsychotic; selective dopamine D2 and D3 receptor antagonist
DRD2, DRD3Phase 3Treatment-resistant SchizophreniaDec 2030
Shanghai Mental Health CenterClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 3Treatment-resistant SchizophreniaDec 2030
MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsApomorphine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Idiopathic Parkinson's Disease–
Reviva PharmaceuticalsBrilaroxazine (RP5063)
Dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist
DRD2, HT1APhase 3Schizophrenia–
I.R.C.C.S. Fondazione Santa LuciaRotigotine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Alzheimer Disease–
University of California, San DiegoPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Anxiety DisordersNov 2026
Carmen Clapplevosulpiride
dopamine D2 receptor antagonist
DRD2Phase 2Diabetic Macular EdemaDec 2026
University of LiegeApomorphine Hydrochloride
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Disorder of ConsciousnessDec 2026
M.D. Anderson Cancer CenterChlorpromazine
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, DRD2, DRD3, DRD4Phase 2DeliriumFeb 2027
M.D. Anderson Cancer CenterHaloperidol
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor inverse agonist
HTR2A, DRD2, DRD3, DRD4Phase 2Delirium; Advanced Malignant Neoplasm; Advanced CancersFeb 2027
Instituto do Cancer do Estado de São PauloAmisulpride
Dopamine D2 and D3 receptor antagonist
DRD2, DRD3Phase 2Post Operative Nausea and Vomiting (PONV)Mar 2027
Jazz PharmaceuticalsJZP3507 (ONC206)
DRD2 agonist
DRD2Phase 2Meningioma; Advanced Pheochromocytoma and Paraganglioma; Central Nervous System NeoplasmsMar 2027
Boryung PharmaceuticalOlanzapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy …May 2027
Simon FisherMetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 2Hypoglycemia UnawarenessJun 2027
Clinical Academic Center (2CA-Braga)Pramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Obsessive-Compulsive DisorderAug 2028
Lone BaandrupQuetiapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 2Psychiatric DisordersFeb 2029
Göteborg UniversityOSU6162
Dopamine D2 receptor antagonist (putative)
DRD2Phase 2Depression; Bipolar DepressionMay 2029
University Hospital, Rouenrotigotine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Kidney DiseasesJul 2030
Stanford UniversityPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Depression - Major Depressive DisorderAug 2030
Md. Moktadirul Hoque ShuvoTrifluoperazine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Functional Dyspepsia–
Mapi PharmaCariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 1SchizophreniaDec 2026
Serina TherapeuticsSER-252 (PEOZ-apomorphine)
Dopamine receptor agonist (D1-like and D2-like dopamine receptors)
DRD1, DRD2, DRD3, DRD4, DRD5Phase 1PARKINSON DISEASE (Disorder)Jan 2027
University of ArizonaZiprasidone
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 1SchizophreniaFeb 2027
Sabine Mueller, MD, PhDONC206
DRD2 antagonist / ClpP agonist
DRD2, CLPPPhase 1Diffuse Midline Glioma (DMG)May 2027
Anxo PharmaceuticalAX251 LAI
Dopamine D2/D3 receptor partial agonist
DRD2, DRD3Phase 1SchizophreniaJul 2028
Sichuan Kelun PharmaceuticalBrexpiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 1Schizophrenia Disorders; Major Depressive Disorder; Bipolar Depression; Alcohol Use Disorder–
Capital Medical UniversityChlorpromazine
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, DRD2, DRD3, DRD4Phase 1Acute Ischemic Stroke–
Verinder SharmaQuetiapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 1Postpartum Depression–

Conditions

Schizophrenia (17) Bipolar I Disorder (5) Schizophenia Disorder (4) Schizophrenia and Related Disorders (4) Bipolar Depression (3) Delirium (3) Treatment-resistant Schizophrenia (3) Amyotrophic Lateral Sclerosis (2) Hyperprolactinemia (2) Prolactinoma (2) Migraine (2) Major Depressive Disorder (2)

Modalities

small molecule (56), protein or peptide (6), mixed (1), antibody (1)

Companies

Massachusetts General Hospital (4) Centre for Addiction and Mental Health (3) M.D. Anderson Cancer Center (3) Northwell Health (3) Shanghai Mental Health Center (3) New York State Psychiatric Institute (2) Prilenia (1) Changchun GeneScience Pharmaceutical (1) Vanda Pharmaceuticals (1) Intra-Cellular Therapies (1) The Chaim Sheba Medical Center (1) Verinder Sharma (1) LB Pharmaceuticals (1) Sichuan Kelun Pharmaceutical (1) Gedeon Richter (1) Jazz Pharmaceuticals (1) Serina Therapeutics (1) Göteborg University (1) Boryung Pharmaceutical (1) University of Arizona (1)

Related targets

HTR2A (31) DRD3 (24) DRD4 (17) HTR2C (11) HTR1A (5) HTR3A (3) HTR4 (3) SLC6A4 (1) OPRK1 (1) DRD1 (1) DRD5 (1) CLPP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.